Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
British Journal of Cancer|February 5, 2020
Targeting DUBs to degrade oncogenic proteinsAnjali Cremer, Kimberly Stegmaier
Journal of Medicinal Chemistry|February 12, 2019
Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring MutationsDennis Bensinger, Daniel Stubba, Anjali Cremer, et al.
Annals of Hematology|August 8, 2023
Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AMLAnjali Cremer, Julius C Enssle, Saskia Pfaff, et al.
Journal of Intensive Care Medicine|July 19, 2017
Diagnostic Yield and Outcomes of Computed Tomography of the Head in Critically Ill Nontrauma PatientsFabian Finkelmeier, Sophie Walter, Kai-Henrik Peiffer, et al.
Annals of Hematology|November 26, 2024
Central nervous system relapse after allogeneic HCT in FLT3-mutated AMLKhouloud Kouidri, Fabian Acker, Rosa Toenges, et al.
Scientific Reports|April 5, 2025
Inflammatory signaling pathways play a role in SYK inhibitor resistant AMLSarah Tausch, Christina Villinger, Gabriela Alexe, et al.
Annals of Hematology|September 5, 2024
Interventional antibiotic treatment replacing antibiotic prophylaxis during allogeneic hematopoietic stem cell transplantation is safe and leads to a reduction of antibiotic administrationRosa Toenges, Fabian Lang, Rakhshinda Ghaffar, et al.
Blood|January 22, 2015
FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferationThomas Oellerich, Sebastian Mohr, Jasmin Corso, et al.
European Journal of Immunology|April 7, 2022
SARS-CoV-2-specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccinationAndrea Jarisch, Eliza Wiercinska, Shabnam Daqiq-Mirdad, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 16, 2024
Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectorsTobias Bexte, Lacramioara Botezatu, Csaba Miskey, et al.
Pageof 2